Rotavirus vaccination was historically recommended by the CDC for all infants beginning at 2 months of age. Updated 2026 childhood vaccination recommendations categorize vaccines as recommended for all children, recommended for children at high risk, or based on shared clinical decision-making for children who are not at high risk; rotavirus vaccination is included in the shared clinical decision-making category. These decisions are individualized through discussion between the health care provider and parent or guardian. Two rotavirus vaccines are available: RotaTeq® (RV5), a 3-dose pentavalent oral vaccine, and Rotarix® (RV1), a 2-dose monovalent oral vaccine, with no preferred product specified. Regardless of product, the first dose may be administered as early as 6 weeks and must be given before 15 weeks of age, with the series completed by 8 months. Clinical studies supporting FDA approval demonstrated 85%–100% efficacy against severe rotavirus gastroenteritis, with efficacy maintained through two seasons/years. Direct comparative evidence is limited to one identified randomized controlled trial in infants in Bangladesh (Table 1), in which RotaTeq produced higher rotavirus IgA seroconversion after completion of the recommended series and at 22 weeks of age; however, an incomplete 2-dose RotaTeq series resulted in lower seroconversion than the complete 2-dose Rotarix series. Safety was similar between groups. The study was limited by the absence of clinical efficacy outcomes, short follow-up, and potentially limited generalizability. Indirect comparisons support the efficacy and safety of both vaccines, without significant differences identified between products. [1], [2], [3], [4], [5], [6]
A 2014 comprehensive review evaluated the effectiveness and impact of the two rotavirus vaccines, RotaTeq (RV5) and Rotarix (RV1), in the United States from 2006 through 2012. Multiple study designs, including active population-based surveillance, retrospective case–control analyses, and health insurance claims data evaluations, assessed outcomes such as hospitalizations, emergency department (ED) visits, and outpatient visits due to rotavirus gastroenteritis and all-cause diarrhea in children under five years of age. A notable 2007–2009 multi-center active surveillance study reported RV5 effectiveness against rotavirus hospitalizations and ED visits ranging from 84% to 90% across the first and second years of life, with protection sustained through the fourth year without evidence of waning immunity. Partial immunization with one or two doses also conferred significant, though reduced, protection. Similarly, RV1 demonstrated high effectiveness, particularly after completion of the two-dose series, showing approximately 70–91% effectiveness against hospitalization or ED visits related to rotavirus gastroenteritis, with sustained protection into the second year of life. The reviewed data further illustrated the vaccines’ broad strain coverage, with RV5 and RV1 providing significant protection against several circulating rotavirus genotypes, including those not directly represented in the vaccines, such as G1P[8] and G2P[4]. Post-vaccine introduction, surveillance systems including the National Respiratory and Enteric Virus Surveillance System (NREVSS) and national hospital discharge databases documented a substantial and sustained decline in rotavirus activity and related hospitalizations—up to 75–90% reductions in rotavirus-coded hospitalizations and notable declines in all-cause diarrheal hospitalizations and ED visits. These decreases extended beyond vaccinated children, with evidence of indirect (herd) protection observed in older unvaccinated children and adults. The epidemiologic impact included alterations in seasonal rotavirus patterns, with delayed onset and a biennial cycle of activity explained by vaccination coverage dynamics. Economic analyses extrapolated from hospitalization reductions suggested cost savings of approximately $240–280 million over two seasons. Rare adverse events such as intussusception were reported but did not outweigh the substantial benefits of vaccination. Overall, the evaluation supports robust, sustained effectiveness of rotavirus vaccines in real-world US settings, demonstrating both direct and indirect protection with significant public health and economic benefits. [7]
A 2021 systematic review and meta-analysis published in JAMA Pediatrics synthesized data from 20 randomized clinical trials and 38 observational case-control studies, encompassing over 100,000 children under 5 years old, to evaluate the effectiveness, safety, and immunogenicity of various rotavirus vaccines worldwide. The comprehensive literature search extended to July 1, 2020, across Embase, PubMed, Cochrane Library, and Web of Science, including studies with sample sizes exceeding 100 children. Using random-effects models, the analysis calculated relative risks (RRs), odds ratios (ORs), and risk differences with 95% confidence intervals (CIs), while indirect treatment comparisons assessed differences between major vaccines, specifically Rotarix (RV1) and RotaTeq (RV5). Stratification by country income level and vaccination schedules was employed to address heterogeneity and contextual variability. The methodology incorporated metaregression to explore the correlation between immunogenicity, measured by seroconversion rates of anti-rotavirus IgA antibodies, and vaccine protection. The results demonstrated that full vaccination with RV1 and RV5 significantly reduced the risk of rotavirus gastroenteritis (RVGE) and associated hospitalizations in children younger than 5 years, with pooled RRs of approximately 0.316 and 0.350 for RVGE, respectively, indicating over 60% reduction. Both vaccines provided higher protection against severe RVGE, with no significant differences detected between RV1 and RV5 in adjusted indirect comparisons. Other vaccines, including Rotavac, Rotasiil, and Lanzhou lamb rotavirus vaccine (LLR), also showed moderate protective effects in relevant geographic regions. Safety analyses revealed no increased risk of serious adverse events, intussusception, or mortality related to vaccination during up to two years of follow-up. The protective effect waned modestly during the second year post-vaccination, especially in low-income countries, underscoring the importance of full-dose vaccination adherence. Moreover, immunogenicity positively correlated with vaccine efficacy, with higher seroconversion rates associated with greater protection. Strain-specific analyses confirmed that vaccines offered cross-protection against heterotypic rotavirus strains, which is critical given the global diversity of circulating serotypes. These findings support the broad implementation of rotavirus vaccination programs, with attention to ensuring complete dosing and continued post-introduction surveillance. [8]
A 2020 literature review and meta-analysis evaluated the real-world effectiveness of rotavirus vaccines—specifically Rotarix (GlaxoSmithKline) and RotaTeq (Merck)—across 60 observational, post-licensure studies from 32 countries between 2006 and 2019. Only studies reporting laboratory-confirmed rotavirus as the endpoint and conducted in countries routinely using these vaccines were included, while data on other infant rotavirus vaccines were excluded due to limited post-licensure evidence. Countries were stratified by under-five child mortality rates into low, medium, and high mortality groups based on 2017 UNICEF data. Random-effects regression models estimated vaccine effectiveness for two pediatric age groups: under 12 months and 12–23 months. The meta-analysis also examined product-specific effectiveness, mixed vaccine series, and non-product-specific vaccine effectiveness, with an emphasis on assessing differences by child mortality strata and age. The analysis demonstrated that Rotarix vaccine effectiveness against laboratory-confirmed rotavirus in children under 12 months was highest in low-mortality countries at 86% (95% CI 81–90), intermediate in medium-mortality settings at 77% (66–85), and lowest in high-mortality settings at 63% (54–70). Effectiveness among children 12–23 months old showed a similar pattern, with 86% (81–90) in low-, 54% (23–73) in medium-, and 58% (38–72) in high-mortality countries. RotaTeq showed comparable trends with 86% (76–92) effectiveness in low-mortality countries under 12 months and 66% (51–76) in high-mortality countries; effectiveness among 12–23-month-old children was 84% (79–89) in low-mortality settings. Little heterogeneity was observed (I² range 0–36%). Partial vaccination series conferred lower protection, especially in medium- and high-mortality countries, underscoring the importance of complete dosing schedules. Mixed vaccine series demonstrated comparable effectiveness to single-product series. The findings highlight a consistent gradient of rotavirus vaccine effectiveness tied to child mortality rates, with greater vaccine performance in settings of lower mortality and in younger children, supporting timely and complete immunization programs worldwide. [9]